Introduction {#s1}
============

Pulmonary arterial hypertension is a devastating, progressive disease with increasingly debilitating symptoms.^[@EHP022C1]^ Increased pulmonary vascular resistance owing to obstructive proliferative changes in the lung microcirculation results in extensive heart structural changes, limits patients exercise capacity, and eventually leads to right heart failure and premature death.^[@EHP022C1]^

The pathogenesis of pulmonary arterial hypertension is poorly understood, but an imbalance between vasoconstrictor/proliferative agents (e.g. endothelin) and vasodilator/antiproliferative substances (e.g. prostacyclin and nitric oxide) have been identified in the lung vasculature.^[@EHP022C2],[@EHP022C3]^

There is no cure for pulmonary arterial hypertension, but current approved treatment options include prostanoids, endothelin-receptor antagonists, and the phosphodiesterase type-5 inhibitors.^[@EHP022C4]^ These therapies improve symptoms, exercise capacity, haemodynamics, and outcome but the clinical relevance of these effects have been recently challenged.^[@EHP022C5]--[@EHP022C7]^ The main criticisms include the limited improvements observed on the exercise capacity and the short duration and the small sample size of the individual studies which have precluded any insight on the prognostic relevance of the treatments.

A meta-analysis on 16 randomized controlled trials (RCTs) performed in pulmonary arterial hypertension^[@EHP022C8]^ concluded that the treatments 'produced limited benefits in clinical endpoints and failed to support a significant survival advantage'. However, the meta-analysis did not consider six RCTs^[@EHP022C9]--[@EHP022C14]^ published before its submission, included both acute^[@EHP022C15],[@EHP022C16]^ and long-term studies and included one study on patients with lung fibrosis.^[@EHP022C16]^

We present the data of a meta-analysis on 23 RCTs^[@EHP022C9]--[@EHP022C14],[@EHP022C17]--[@EHP022C33]^ with drugs performed exclusively in pulmonary arterial hypertension patients (only in one study a minority of patients with inoperable chronic thrombo-embolic pulmonary hypertension was included^[@EHP022C23]^) published as of October 2008. We excluded acute studies assessing only haemodynamic variables.

Methods {#s2}
=======

RCTs in patients with pulmonary arterial hypertension (Group 1 according to the Venice clinical classification^[@EHP022C34]^ of pulmonary hypertension) published in English from January 1990 to October 2008 were identified by the commonly adopted approach of computer-based literature search on the MEDLINE database (*Figure [1](#EHP022F1){ref-type="fig"}*). As we were interested in the analysis of the effects on mortality, acute studies assessing only haemodynamic variables were excluded. Twenty-three RCTs with drugs (*Tables [1](#EHP022TB1){ref-type="table"}* and *[2](#EHP022TB2){ref-type="table"}*) with these characteristics were identified. Each study was used as a unit for statistical analysis. The data were analysed by intention-to-treat including all randomized patients.

![Flow chart of the search strategy and selection of the trials.](ehp02201){#EHP022F1}

###### 

Randomized controlled trial characteristics

  First author/year                   Official acronym   Number of patients   Active drug               Comparator               Study period (weeks)   Etiology (%)
  ----------------------------------- ------------------ -------------------- ------------------------- ------------------------ ---------------------- ----------------------------------
  Rubin *et al*.^[@EHP022C17]^        --                 23                   Epoprostenol              Randomized controls\*    8                      IPAH (100)
  Barst *et al*.^[@EHP022C18]^        --                 81                   Epoprostenol              Randomized controls\*    12                     IPAH (100)
  Badesch *et al*.^[@EHP022C19]^      --                 111                  Epoprostenol              Randomized controls\*    12                     APAH (100)
  Channick *et al*.^[@EHP022C20]^     --                 32                   Bosentan                  Placebo                  12                     IPAH (84), APAH (16)
  Langleben *et al*.^[@EHP022C9]^     --                 71                   Terbogrel                 Placebo                  12                     IPAH (100)
  Simmoneau *et al*.^[@EHP022C21]^    --                 470                  Treprostinil              Placebo                  12                     IPAH (58), APAH (42)
  Galiè *et al*.^[@EHP022C22]^        ALPHABET           130                  Beraprost                 Placebo                  12                     IPAH (48), APAH (52)
  Olschewski *et al*.^[@EHP022C23]^   AIR                203                  Iloprost                  Placebo                  12                     IPAH (50), APAH (22), CTEPH (28)
  Rubin *et al*.^[@EHP022C24]^        BREATHE-1          213                  Bosentan                  Placebo                  16                     IPAH (70), APAH (30)
  Barst *et al*.^[@EHP022C25]^        --                 116                  Beraprost                 Placebo                  36                     IPAH (74), APAH (26)
  Sastry *et al*.^[@EHP022C26]^       --                 22                   Sildenafil                Placebo                  12                     IPAH (100)
  Humbert *et al*.^[@EHP022C27]^      BREATHE-2          33                   Epoprostenol + Bosentan   Epoprostenol + placebo   16                     IPAH (82), APAH (18)
  Barst *et al*.^[@EHP022C28]^        STRIDE-1           178                  Sitaxsentan               Placebo                  12                     IPAH (53), APAH (47)
  Galiè *et al*.^[@EHP022C29]^        SUPER-1            278                  Sildenafil                Placebo                  12                     IPAH (64), APAH (30), Other (6)
  Wilkins *et al*.^[@EHP022C30]^      SERAPH             26                   Bosentan                  Sildenafil               16                     IPAH (88), APAH (12)
  Singh *et al*.^[@EHP022C10]^        --                 20                   Sildenafil                Placebo                  8                      IPAH (50), PAH-ES (50)
  Galiè *et al*.^[@EHP022C11]^        BREATHE-5          54                   Bosentan                  Placebo                  16                     PAH-ES (100)
  Barst *et al*.^[@EHP022C13]^        STRIDE-2           185                  Sitaxsentan               Placebo                  18                     IPAH (59), APAH (30), Other (11)
  McLaughlin *et al*.^[@EHP022C12]^   STEP               67                   Inhaled iloprost^†^       Placebo^†^               12                     IPAH (55), APAH (45)
  Hoeper *et al*.^[@EHP022C14]^       COMBI              40                   Inhaled iloprost^†^       Placebo^†^               12                     IPAH (100)
  Galiè *et al*.^[@EHP022C31]^        ARIES              394                  Ambrisentan               Placebo                  12                     IPAH (64), APAH (32), Other (4)
  Galiè *et al*.^[@EHP022C32]^        EARLY              185                  Bosentan^‡^               Placebo^‡^               24                     IPAH (61),APAH (35), Other(4)
  Simonneau *et al*.^[@EHP022C33]^    PACES              267                  Sildenafil^§^             Placebo^§^               16                     IPAH (79), APAH (21)

APAH, associated pulmonary arterial hypertension; CTEPH, chronic thrombo-embolic pulmonary hypertension; IPAH, idiopathic pulmonary arterial hypertension; PAH-ES, pulmonary arterial hypertension associated with Eisenmenger syndrome.

\*The randomized control group was included but it was not blinded because for ethical reasons, a tunnellized central venous catheter and a portable pump for placebo infusion was not utilized.

^†^All patients were on background treatment with Bosentan.

^‡^11% of patients were on background treatment with Sildenafil.

^§^All patients were on background treatment with Epoprostenol.

###### 

Randomized controlled trial characteristics

  First author/year                   Official acronym   NYHA/WHO functional class (%)   Primary endpoint   Invasive haemodynamic evaluation   Explicitly reported hospitalizations   Reported survival               
  ----------------------------------- ------------------ ------------------------------- ------------------ ---------------------------------- -------------------------------------- ------------------- ----- ----- -----
  Rubin *et al*.^[@EHP022C17]^        --                 --                              9                  65                                 26                                     6MWD                Yes   No    Yes
  Barst *et al*.^[@EHP022C18]^        --                 --                              --                 74                                 26                                     6MWD                Yes   No    Yes
  Badesch *et al*.^[@EHP022C19]^      --                 --                              5                  78                                 17                                     6MWD                Yes   No    Yes
  Channick *et al*.^[@EHP022C20]^     --                 --                              --                 100                                --                                     6MWD                Yes   No    Yes
  Langleben *et al*.^[@EHP022C9]^     --                 --                              49                 51                                 --                                     6MWD                Yes   No    Yes
  Simmoneau *et al*.^[@EHP022C21]^    --                 --                              11                 81                                 8                                      6MWD                Yes   No    Yes
  Galiè *et al*.^[@EHP022C22]^        ALPHABET           --                              49                 51                                 --                                     6MWD                Yes   No    Yes
  Olschewski *et al*.^[@EHP022C23]^   AIR                --                              --                 59                                 41                                     6MWD&FC             Yes   No    Yes
  Rubin *et al*.^[@EHP022C24]^        BREATHE-1          --                              --                 91                                 9                                      6MWD                No    Yes   Yes
  Barst *et al*.^[@EHP022C25]^        --                 --                              52                 48                                 --                                     VO~2~ max           Yes   No    Yes
  Sastry *et al*.^[@EHP022C26]^       --                 --                              82                 18                                 --                                     TT                  No    No    Yes
  Humbert *et al*.^[@EHP022C27]^      BREATHE-2          --                              --                 75                                 25                                     PVR                 Yes   No    Yes
  Barst *et al*.^[@EHP022C28]^        STRIDE-1           --                              33                 66                                 1                                      VO~2~ max           Yes   No    Yes
  Galiè *et al*.^[@EHP022C29]^        SUPER-1            --                              39                 58                                 3                                      6MWD                Yes   Yes   Yes
  Wilkins *et al*.^[@EHP022C30]^      SERAPH             1                               --                 100                                --                                     RV mass             No    No    Yes
  Singh *et al*.^[@EHP022C10]^        --                 --                              40                 55                                 5                                      6MWD                No    No    Yes
  Galiè *et al*.^[@EHP022C11]^        BREATHE-5          --                              --                 100                                --                                     SaO~2~ and PVR      Yes   No    Yes
  Barst *et al*.^[@EHP022C13]^        STRIDE-2           --                              37                 59                                 4                                      6MWD                No    Yes   Yes
  McLaughlin *et al*.^[@EHP022C12]^   STEP               --                              1                  94                                 5                                      6MWD                Yes   Yes   Yes
  Hoeper *et al*.^[@EHP022C14]^       COMBI              --                              --                 100                                --                                     6MWD                No    Yes   Yes
  Galiè *et al*.^[@EHP022C31]^        ARIES              2                               38                 55                                 5                                      6MWD                No    Yes   Yes
  Galiè *et al*.^[@EHP022C32]^        EARLY              --                              100                --                                 --                                     PVR and 6MWD        Yes   Yes   Yes
  Simonneau *et al*.^[@EHP022C33]^    PACES              1                               25                 68                                 6                                      6MWD                Yes   Yes   Yes

6MWD, six-minute walk distance; NYHA, New York Heart Association; PVR, pulmonary vascular resistance; RV, right ventricle; SaO~2~, systemic arterial blood oxygen saturation; TT, treadmill exercise test duration; VO~2~max, maximal oxygen consumption at cardiopulmonary exercise test; WHO, World Health Organization.

Main outcome measure for the present analysis was all-cause mortality, which was reported in all RCTs. The following additional secondary parameters which were reported explicitly and clearly in the text and/or tables of only part of the RCTs were also assessed: hospitalizations owing to pulmonary arterial hypertension, exercise capacity as assessed by the 6-min walk distance (6MWD),^[@EHP022C35]^ NYHA/WHO functional class improvement,^[@EHP022C36]^ right atrial pressure, mean pulmonary arterial pressure, cardiac index, and pulmonary vascular resistance.

The primary analysis was performed in 21 RCTs in which a clear identification of a placebo comparator arm was possible. Two additional RCTs^[@EHP022C27],[@EHP022C30]^ assessed two different, concurrently initiated treatment regimens in naïve patients and the decision on which arm is considered the reference 'placebo' comparator arm may be arbitrary. RCTs with patients on background treatment with approved drugs for pulmonary arterial hypertension in which the addition of a new active compound (combination therapy) was tested as compared with placebo were included.^[@EHP022C12],[@EHP022C14],[@EHP022C32],[@EHP022C33]^ Studies with compounds that were eventually not approved owing to lack of efficacy^[@EHP022C9],[@EHP022C22],[@EHP022C25]^ and doses of approved drugs, which were not endorsed because less effective or for increased side effects^[@EHP022C13],[@EHP022C24],[@EHP022C28],[@EHP022C31]^ were also included. In the three RCTs with epoprostenol,^[@EHP022C17]--[@EHP022C19]^ a randomized control group was included but it was not blinded because for ethical reasons tunnelled central venous catheters and portable pumps for placebo infusion were not utilized.

A secondary, sensitivity analysis on total mortality was performed including all 23 studies. In this case the reference 'placebo' comparator arm in the two studies assessing two different, concurrently initiated treatment regimens in naïve patients was arbitrarily identified: in the BREATHE-2 study^[@EHP022C27]^ the group treated with epoprostenol alone (as compared with the association of epoprostenol and bosentan) and in the SERAPH study^[@EHP022C30]^ the bosentan arm (as compared with the sildenafil arm) were considered as control arms, respectively. These regimens could be considered as 'standard of care' when the studies were conceived and performed.

Statistical methods {#s2a}
-------------------

Treatment effects for total mortality were evaluated as relative risks (RR) according to the inverse variance fixed-effect method.^[@EHP022C37]^ In order to identify biases owing to the exclusion of trials from the analysis, the continuity correction method was also used by adding 0.5 in each cell with null events. To confirm the robustness of the data in case of statistically significant results (*P* \< 0.05) of the primary analysis,^[@EHP022C38]^ the Mantel--Haenszel and the Peto fixed-effect methods were also tested.

Treatment effects for explicitly reported hospitalizations and NYHA/WHO improvement were evaluated as RR according to the inverse variance fixed-effect method.

Number needed to benefit (NNT) and number of avoided events per 1000 treated patients were calculated applying the RR to the control group event rate.

For exercise capacity (as assessed by 6MWD), right atrial pressure, pulmonary arterial pressure, cardiac index, and pulmonary vascular resistance (as assessed by right heart catheterization), we computed the effect size of tested drugs by using the weighted mean difference, which was calculated after subtracting from baseline the end-study values in treated and control groups. When studies did not directly supply the standard error of the mean (SEM) for the calculation of effect size, it was estimated from the published data.^[@EHP022C39]^ When either the values at the end of follow-up or the SEM were not reported in the article, they were manually calculated from figures (if available).

Multi-arm studies^[@EHP022C13],[@EHP022C24],[@EHP022C28],[@EHP022C29],[@EHP022C31]^ were assessed combining all active arms in one and comparing it with the control group. The arms testing doses of drugs, which were eventually not approved because less effective or for increased side effects^[@EHP022C13],[@EHP022C24],[@EHP022C28],[@EHP022C31]^ were included. The Cochran Q test and I-squared were used to assess the magnitude of effect size heterogeneity. When the heterogeneity test reached the formal level for statistical significance to assess heterogeneity (*P* \< 0.10), the null hypothesis of homogeneity of the treatment effects across the studies was rejected and the analysis was repeated by calculating a random-effect model.^[@EHP022C40]^

Additional analyses were performed according to the pharmacological category of tested drugs and disease severity (estimated using the median value of the 6MWD at baseline).

All analyses were performed using Stata 9.0 (Stata Statistical Software: Release 9.0, 2005. StataCorp LP, College Station, TX, USA).

Results {#s3}
=======

Characteristics of the studies {#s3a}
------------------------------

*Tables [1](#EHP022TB1){ref-type="table"}* and *[2](#EHP022TB2){ref-type="table"}* show the 23 RCTs characteristics recruiting 3199 patients with pulmonary arterial hypertension that have been published over a 18-year period (January 1990--October 2008, *Figure [1](#EHP022F1){ref-type="fig"}*). In the 21 studies included in the primary analysis, 3140 patients were enrolled. Only in one study^[@EHP022C23]^ 57 patients with non-operable chronic thrombo-embolic pulmonary hypertension (Group 4^[@EHP022C34]^) were recruited. Eight RCTs assessed the effects of prostanoids (intravenous epoprostenol, subcutaneous treprostinil, inhaled iloprost, and oral beraprost), eight RCTs assessed the effects of endothelin receptor antagonists (oral bosentan, sitxsentan, and ambrisentan), four RCTs assessed the effects of the phosphodiesterase type-5 inhibitor sildenafil, and one study the effects of the thromboxane synthase inhibitor terbogrel. Two studies^[@EHP022C27],[@EHP022C30]^ compared two different, concurrently initiated treatment regimens in naïve patients: in the BREATHE-2 study, the groups were treated with epoprostenol alone or with a combination of epoprostenol and bosentan, respectively, and in the SERAPH study, the groups were treated with bosentan or sildenafil, respectively. In four studies background therapy with bosentan,^[@EHP022C12],[@EHP022C14]^ sildenafil,^[@EHP022C32]^ or epoprostenol,^[@EHP022C33]^ respectively, was allowed.

The average length of the study periods was 14.3 ± 5.9 weeks (range 8--36 weeks).

In 17 studies, the exclusive or predominant aetiology was idiopathic pulmonary arterial hypertension, two studies included exclusively patients with the scleroderma spectrum of diseases^[@EHP022C19]^ or patients with Eisenmenger\'s syndrome.^[@EHP022C11]^

The majority of the patients included in the RCTs were in NYHA/WHO functional class III, only one study included exclusively NYHA/WHO functional class II patients.^[@EHP022C32]^

The 6MWD alone or in combination was the primary endpoint in 17 studies; additional primary endpoints included maximal oxygen consumption, treadmill exercise test duration, pulmonary vascular resistance, right ventricular muscle mass, and systemic blood oxygen saturation.

All-cause mortality {#s3b}
-------------------

Overall mortality (*Table [3](#EHP022TB3){ref-type="table"}*, *Figure [2](#EHP022F2){ref-type="fig"}*) in the 21 studies included in the primary analysis was 2.48% (78 of the 3140 patients). Mortality in the actively treated group was 1.54% (28 of the 1825patients) and in the placebo group was 3.80% (50 of the 1315 patients). These cumulative data do not consider the different randomization fractions and the different durations of the RCTs and should be intended as descriptive.

![Cumulative RR estimate of death in active treatment groups when compared with control groups (RR \[95% CI\]). *P* = 0.023 for the overall estimate of the primary analysis by inverse variance method. Studies with no events in both groups (*Table [3](#EHP022TB3){ref-type="table"}*) were excluded.](ehp02202){#EHP022F2}

###### 

Number of patients who died or were hospitalized in the randomized phase of the clinical trials (intent-to-treat)

  First author/year                   Active drug   Comparator   Active drug   Comparator                   
  ----------------------------------- ------------- ------------ ------------- ------------ ---- ----- ---- -----
  Rubin *et al*.^[@EHP022C17]^        1             10           3             9            NA   NA    NA   NA
  Barst *et al*.^[@EHP022C18]^        0             41           8             32           NA   NA    NA   NA
  Badesch *et al*.^[@EHP022C19]^      4             52           5             50           NA   NA    NA   NA
  Channick *et al*.^[@EHP022C20]^     0             21           0             11           NA   NA    NA   NA
  Langleben *et al*.^[@EHP022C9]^     1             45           0             25           NA   NA    NA   NA
  Simmoneau *et al*.^[@EHP022C21]^    9             224          10            227          NA   NA    NA   NA
  Galiè *et al*.^[@EHP022C22]^        1             64           1             64           NA   NA    NA   NA
  Olschewski *et al*.^[@EHP022C23]^   1             100          4             98           NA   NA    NA   NA
  Rubin *et al*.^[@EHP022C24]^        1             143          2             67           6    138   9    60
  Barst *et al*.^[@EHP022C25]^        1             59           2             54           NA   NA    NA   NA
  Sastry *et al*.^[@EHP022C26]^       0             10           1             11           NA   NA    NA   NA
  Humbert *et al*.^[@EHP022C27]^      3             19           0             11           NA   NA    NA   NA
  Barst *et al*.^[@EHP022C28]^        1             117          0             60           NA   NA    NA   NA
  Galiè *et al*.^[@EHP022C29]^        3             205          1             69           6    201   7    63
  Wilkins *et al*.^[@EHP022C30]^      1             13           0             12           NA   NA    NA   NA
  Singh *et al*.^[@EHP022C10]^        0             10           0             10           NA   NA    NA   NA
  Galiè *et al*.^[@EHP022C11]^        0             37           0             17           NA   NA    NA   NA
  Barst *et al*.^[@EHP022C13]^        0             123          0             62           2    121   4    58
  McLaughlin *et al*.^[@EHP022C12]^   0             34           0             33           0    34    4    29
  Hoeper *et al*.^[@EHP022C14]^       0             19           0             21           0    19    0    21
  Galiè *et al*.^[@EHP022C31]^        4             257          5             128          9    252   11   121
  Galiè *et al*.^[@EHP022C32]^        1             92           1             91           1    92    3    89
  Simonneau *et al*.^[@EHP022C33]^    0             134          7             126          8    126   11   120

NA, not assessed.

\*Explicitly reported hospitalizations for pulmonary arterial hypertension.

The cumulative RR estimate of death was a reduction of 43% (RR 0.57; 95% CI 0.35, 0.92; *P* = 0.023) with the inverse variance method (*Figure [2](#EHP022F2){ref-type="fig"}*), no heterogeneity (I-squared = 0.0%; *P* = 0.830) was detected among studies. The analysis with the continuity correction (*P* \< 0.022), the Mantel--Haenszel and the Peto methods (both *P* \< 0.001) confirmed the statistical significance.

Number of patients to be treated (NNT) to prevent one death was 61.6 and 16.2 (95% CI 2.7--24.0) deaths were prevented in each 1000 patients treated; these data were based on a RR = 0.573 applied to the control group event rate.

With respect to the effects of the different classes of drugs (prostanoids, thromboxane synthase inhibitors, endothelin receptor antagonists, and phosphodiesterase type-5 inhibitors), no statistically significant between-group heterogeneity (I-squared = 0.0%; *P* = 0.771) emerged in subgroup analyses in total mortality (*Figure [3](#EHP022F3){ref-type="fig"}*) or between the subgroups testing each of the treatments (I-squared = 0.0%; *P* = 0.830).

![Cumulative RR estimate of death in active treatment groups when compared with control groups stratified according to treatment class (inverse variance method). Heterogeneity between groups: *P* = 0.771. Studies with no events in both groups (*Table [3](#EHP022TB3){ref-type="table"}*) were excluded. RR, relative risk.](ehp02203){#EHP022F3}

Cumulative RR estimate of death in active treatment groups when compared with control groups stratified by baseline exercise capacity according to the median value of the 6MWD of 343 m (*Figure [4](#EHP022F4){ref-type="fig"}*) did not show between-group heterogeneity (I-squared = 0.0%; *P* = 0.825).

![Cumulative RR estimate of death in active treatment groups when compared with control groups stratified by the median of baseline exercise capacity of the studies (inverse variance method). Studies with no events in both groups (*Table [3](#EHP022TB3){ref-type="table"}*) were excluded. Heterogeneity between groups: *P* = 0.825. 6MWD, six-minute walk distance; RR, relative risk.](ehp02204){#EHP022F4}

In the sensitivity analysis including all 23 studies, overall mortality (*Table [3](#EHP022TB3){ref-type="table"}*) was 2.56% (82 of the 3199 patients). Mortality in the actively treated group was 1.72% (32 of the 1861 patients) and in the placebo group was 3.74% (50 of the 1338 patients).

The cumulative RR estimate of death was a reduction of 38% (RR 0.62; 95% CI 0.39, 1.00; *P* = 0.048) with the inverse variance method, no heterogeneity was apparent among studies (I-squared = 0.0%; *P* = 0.784). Analysis with the continuity correction (*P* \< 0.044), the Mantel--Haenszel and Peto methods (*P* \< 0.004 and *P* \< 0.003, respectively) confirmed the statistical significance.

Explicitly reported hospitalizations for pulmonary arterial hypertension {#s3c}
------------------------------------------------------------------------

Overall hospitalization rate in the eight RCTs (35%) reporting this information (*Tables [2](#EHP022TB2){ref-type="table"}* and *[3](#EHP022TB3){ref-type="table"}*) was 4.98% (81 of the 1625). Hospitalization rate in the actively treated group was 3.2% (32 of the 1015) and in the placebo group was 8.03% (49 of the 610). These cumulative data do not consider the different randomization fraction and the different durations of the RCTs and should be intended as descriptive.

The cumulative RR estimate of hospitalizations (*Figure [5](#EHP022F5){ref-type="fig"}*) was a reduction of 61% (RR 0.39; 95% CI 0.25, 0.61; *P* \< 0.001) with the inverse variance method, whereas no heterogeneity was apparent among studies (I-squared = 0.0%; *P* = 0.599).

![Cumulative RR estimate of hospitalizations in active treatment groups when compared with control groups. *P* \< 0.001 for the overall estimate by inverse variance method. Studies with no events in both groups (*Table [3](#EHP022TB3){ref-type="table"}*) were excluded. RR, relative risk.](ehp02205){#EHP022F5}

NNT to prevent one hospitalization was 19.9 and 50.3 (95% CI 32.5, 61.9) hospitalizations were prevented in each 1000 patients treated; these data were based on a RR = 0.393 applied to the control group event rate.

Six-minute walk distance {#s3d}
------------------------

Investigational treatments significantly improved exercise capacity as assessed by the 6MWD. The overall heterogeneity test provided statistically significant results (I-squared = 76.6%; *P* \< 0.001). The weighted mean improvement of exercise capacity assessed by the random-effect model in patients allocated to active treatments in the 19 RCTs (83%) reporting this parameter (see [Supplementary material online, *Figure S1*](http://eurheartj.oxfordjournals.org/cgi/content/full/ehp022/DC1)) was 35.61 m (95% CI 27.13, 44.08; *P* \< 0.001) ranging from −10 to +108 m. This average improvement appears to be an increase of about 10.8% when compared with the mean baseline values. Heterogeneity was related to both, drug classes (*P* \< 0.001) and to baseline exercise capacity (*P* = 0.001).

NYHA/WHO functional class {#s3e}
-------------------------

In the 13 RCTs (53%) reporting NYHA/WHO functional class data (see [Supplementary material online, *Figure S2*](http://eurheartj.oxfordjournals.org/cgi/content/full/ehp022/DC1)), investigational treatments significantly improved this parameter by at least one functional class (RR 2.35; 95% CI 1.59, 3.48; *P* \< 0.001). Statistical tests indicated the existence of heterogeneous study results (I-squared = 56.2%; *P* = 0.007) and data were assessed by the random-effect model. Heterogeneity was related to both, drug classes (*P* = 0.044) and to baseline exercise capacity (*P* = 0.086).

Haemodynamic parameters {#s3f}
-----------------------

Investigational treatments significantly improved haemodynamic parameters as assessed by right heart catheterization. The weighted mean reduction in right atrial pressure in patients allocated to active treatments in the 11 RCTs (48%) reporting this parameter (see [Supplementary material online, *Figure S3*](http://eurheartj.oxfordjournals.org/cgi/content/full/ehp022/DC1)) was −1.84 mmHg (95% CI −1.89, −1.80, *P* \< 0.001) ranging from 1.00 to −6.20 mmHg. The weighted mean reduction in mean pulmonary arterial pressure in patients allocated to active treatments when compared with treatment groups in the 13 RCTs (57%) reporting this parameter (see [Supplementary material online, *Figure S4*](http://eurheartj.oxfordjournals.org/cgi/content/full/ehp022/DC1)) was −2.86 mmHg (95% CI −2.93, −2.77; *P* \< 0.001) ranging from −1.00 to −9.30 mmHg. The weighted mean increase in cardiac index in patients allocated to active treatments in the 12 RCTs (52%) reporting this parameter (see [Supplementary material online, *Figure S5*](http://eurheartj.oxfordjournals.org/cgi/content/full/ehp022/DC1)) was 0.18 L/min/m^2^ (95% CI 0.17, 0.19, *P* \< 0.001) ranging from 0.00 to 1.10 L/min/m^2^. The weighted mean reduction in pulmonary vascular resistance in patients allocated to active treatments in the 13 RCTs (57%) reporting this parameter (see [Supplementary material online, *Figure S6*](http://eurheartj.oxfordjournals.org/cgi/content/full/ehp022/DC1)) was −4.09 resistance units (95% CI −4.18, −3.99; *P* \< 0.001) ranging from −1.40 to −7.50 resistance units. Statistical tests indicated the existence of heterogeneous study results for each of the haemodynamic parameters (I-squared ranged from 87.6% to 98.3%; *P* \< 0.001) and data were assessed by the random-effect model.

Discussion {#s4}
==========

The results of this meta-analysis on RCTs performed in pulmonary arterial hypertension patients show that the mortality in the control groups is high, being approximately 3.8% in the 14.3 weeks of the mean observation period (about 1.1% per month). This confirms the severity of the condition even in the stable and selected patients population included in RCTs. A reduction in the overall mortality of 43% was observed in the patients randomized to the active treatments when compared with those randomized to the placebo control arms (21 RCTs); a reduction of 38% was also confirmed after the addition of the two remaining RCTs, which included a concurrently initiated active control arm. These results were observed even if the average duration of the RCTs was limited to 14.3 weeks and even with the inclusion of RCTs on compounds which were eventually not approved by the Regulatory Agencies because of lack of consistent efficacy such as the thromboxane synthase inhibitor, terbogrel^[@EHP022C9]^ and the oral available prostanoid, beraprost.^[@EHP022C22],[@EHP022C25]^

Subgroups analysis according to the different classes of drugs or with baseline exercise capacity as assessed by 6MWD did not show statistically significant heterogeneity in the effects on mortality. These data suggest that the results have not been driven by one class of drugs or by a group of patients with a specific disease severity.

The reasons for these non-heterogeneous results among different classes of drugs targeting diverse pathobiological pathways are not clear and may include specific disease characteristics, such as a ceiling effect which can limit and homogenize the extent of the beneficial effects that any medical treatment can achieve. In addition, the statistical power of the meta-analysis might not be sufficient to show a difference among drug classes or disease severity groups.

The survival benefit as suggested by the NNT evaluation appears to be significant because 61.6 patients are needed to be treated for an average period of 14.3 weeks for preventing one death.

The favourable results on survival observed in the current meta-analysis when compared with a previous reported meta-analysis^[@EHP022C8]^ may be explained by different reasons including a more appropriate selection of the trials (excluding acute studies and studies with different pulmonary hypertension aetiologies) and a larger sample size of both, number of studies (+44%) and number of patients (+63%).

The rate of explicitly reported hospitalizations owing to pulmonary arterial hypertension observed in the control groups of eight studies of this meta-analysis appears high being approximately 8% in an average period of 14.3 weeks. The reduction by 61% in the rate of hospitalizations observed in the groups of patients randomized to the active treatments appears to support the clinical efficacy of the targeted treatments for pulmonary arterial hypertension: one hospitalization can be prevented treating 19.9 patients for the average observation period of 14.3 weeks. However, these data were reported only in 35% of the RCTs of this meta-analysis and a reporting bias based on whether results tended to be favourable cannot be excluded.

The meta-analysis has confirmed the improvement in exercise capacity as assessed by 6MWD observed in all but two of the 18 studies reporting this parameter. These results are not surprising as the 6MWD has represented the primary endpoint for the majority of the RCTs and both patients\' sample size and statistical power were calculated according to the predicted change of this parameter. The weighted average improvement was about 10.8% when compared with baseline 6MWD but markedly heterogeneous results were observed among different studies ranging from −10 to +108 m.

About half of the RCTs of this meta-analysis have included WHO/NYHA functional class and cardiopulmonary haemodynamic data. The improvement of one functional class was observed more often in patients randomized to active treatments even if only about one-third of the subjects achieved this result. Also in this case a reporting bias based on whether results tended to be favourable cannot be excluded.

Statistically significant improvements in the haemodynamic data, including mean pulmonary arterial pressure, cardiac index, pulmonary vascular resistance, and right atrial pressure were observed. The weighted mean improvements of these parameters appear to be small to moderate ranging from a reduction of about −5% in pulmonary arterial pressure and an increase of 8% of the cardiac index to a reduction of about −29% of the pulmonary vascular resistance.

The limitations of this meta-analysis include the prolonged period of time between the publication of the first and the last RCT (about 18 years), the different duration of the trials (ranging from 8 to 36 weeks), the lack of blindness in some studies,^[@EHP022C17]--[@EHP022C19],[@EHP022C30]^ the pooling of multiple active treatment arms (potential alteration of the trial structure), the report of secondary outcome parameters only in part of the RCTs (possible reporting bias), and potential heterogeneity in the conduct of the trials and in the definition of hospitalization for pulmonary arterial hypertension in different RCTs (no individual patients data were reviewed). On the other hand, this meta-analysis, which considered all randomized patients (intention-to-treat), also included studies with compounds which were eventually not approved because of lack of efficacy^[@EHP022C9],[@EHP022C22],[@EHP022C25]^ and doses of approved drugs which were not endorsed because less effective or for increased side effects.^[@EHP022C13],[@EHP022C24],[@EHP022C28],[@EHP022C31]^

A publication bias, favouring the publication of positive studies, also cannot be excluded. The funnel-plot analysis (plots of effect estimates against standard error of the estimate) did not show asymmetry (see [Supplementary material online, *Figure S7*](http://eurheartj.oxfordjournals.org/cgi/content/full/ehp022/DC1)) and a possible publication bias should not have influenced substantially the results of this meta-analysis.

In conclusion, the results of this meta-analysis suggest an improvement of survival in the patients treated with the targeted therapies approved for pulmonary arterial hypertension. A reduction in the hospitalization rate and favourable results on exercise capacity, functional capacity, and haemodynamics were also observed in the groups of RCTs reporting these data.

Despite these results, the current treatment strategy remains inadequate because the mortality rate continues to be high and the functional and haemodynamic impairments are still extensive in many patients. The non-equivocal progresses observed recently in the medical treatments of this condition are not yet sufficient. Additional efforts are required to explore new strategies including RCTs with initial combination therapy, with new classes of drugs, and with new designs including morbidity and mortality endpoints and prolonged observation periods.

Supplementary material {#s5}
======================

[Supplementary material is available at *European Heart Journal* online](http://eurheartj.oxfordjournals.org/cgi/content/full/ehp022/DC1).

Funding {#s6}
=======

Funding to pay the Open Access publication charges for this article was provided by the Cardiovascular Department of the University of Bologna.

**Conflict of interest:** N.G. has participated in advisory board activities for Actelion, Pfizer, United Therapeutics, Eli-Lilly, Bayer-Schering, Encysive, and Glaxo-SmithKline, given paid lectures for Actelion, Pfizer, Bayer-Schering, and Encysive. The Institute of Cardiology of the University of Bologna has received research grants from Actelion, Pfizer, United Therapeutics, Eli-Lilly, Bayer-Schering, Encysive and Glaxo-Smith-Kline. A.M., L.N., M.P., M.L.B.R., and A.B. had nothing to be declared.

Supplementary Material
======================

###### \[Supplementary Data\]
